Antiviral and immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection

Transplantation

Volumn 68, Issue 11, 1999, Pages 1753-1761

  Martelius, Timi ^a   Scholz, Martin ^b   Krogerus, Leena ^a   Höckerstedt, Krister ^d   Loginov, Raisa ^d   Bruggeman, Cathrien ^c   Cinatl Jr , Jindrich ^b   Doerr, Hans W ^b   Lautenschlager, Irmeli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b GOETHE UNIVERSITY   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

ALLOGRAFT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; GRAFT REJECTION; IMMUNOMODULATION; INFECTION RISK; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033572937     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912150-00020     Document Type: Article

References (43)

1. Von Willebrand E, Pettersson E, Ahonen J, Häyry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986; 42: 364.
2. Reinke P, Fiestze E, Ode-Hakim S, et al. Late acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
3. Pouteil-Noble C, Ecochard R, Donia-Maged A, et al. Cytomegalovirus infection: an etiological factor for rejection? Transplantation 1993; 55: 851.
4. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
5. Cakaloglu Y, Devlin J, O'Grady J, et al. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995; 59: 40.
6. O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA-antigens: interdependent co-factors pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988; II: 302.
7. Arnold JC, Portmann BC, O'Grady JG, et al. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992; 16: 285.
8. Lautenschlager I, Höckerstedt K, Jalanko H, et al. Persistent CMV in liver allografts ending up with chronic rejection. Hepatology 1997; 25: 190.
9. Martelius T, Mäkisalo H, Höckerstedt K, Taskinen E, Lautenschlager I. A rat model of monitoring liver allograft rejection. Transplant Int 1997; 10: 103.
10. Bruggeman C, Meijer H, Bosman F, Van Boven C. Biology of rat cytomegalovirus infection. Intervirology 1985; 24: 1.
11. Martelius T, Krogerus L, Höckerstedt K, Bruggeman C, Lautenschlager I. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 1998; 27: 996.
12. Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996; 62: 1102.
13. Grundy JE. Current antiviral therapy fails to prevent the proinflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack. In: Scholz M, Rabenau H, Doerr HW, Cinatl J Jr, eds. CMV-related immunopathology: monographs in virology, Vol. 21. Basel, Switzerland: S Karger, 1998; 67.
14. Scholz M, Hamann A, Blaheta RA, Auth MK, Encke A, Markus BH. Cytomegalovirus- and interferon related effects on human endothelial cells: cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-γ. Hum Immunol 1992; 35: 230.
15. Steinhoff G, Behrend M, Schrader B, Pichlmayr R. Intercellular immune adhesion molecules in human liver transplants: overview on expression patterns of leukocyte receptor and ligand molecules. Hepatology 1993; 18: 440.
16. Lautenschlager I, Höckerstedt K, Taskinen E, von Willebrand E. 1996. Increased expression of adhesion molecules in liver allografts during cytomegalovirus infection. Transplant Immunol 1996; 4: 59.
17. Smith PD, Saini SJ, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of tumor necrosis factor-α by human monocytes and mucosal macrophages. J Clin Invest 1990; 85: 1642.
18. Iwamoto GK, Monick MM, Clark BD, Auron PE, Stinski MF, Hunninghake GW. Modulation of interleukin 1β gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest 1990; 85: 1853.
19. Geist LJ, Monick MM, Stinski MF, Hunninghake GW. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am J Respir Cell Mol Biol 1991; 5: 292.
20. Scholz M, Cinatl J, Gross V, et al. Impact of oxidative stress on human cytomegalovirus replication and on cytokine-mediated stimulation of endothelial cells. Transplantation 1996; 61: 1763.
21. Vossen RCRM, Persoons MCJ, Slobbe-van Drunen MEP, Bruggeman CA, van Dam-Mieras MCE. Intracellular thiol redox status affects rat cytomegalovirus infection of vascular cells. Virus Res 1997; 48: 173.
22. Speir E, Shibutani T, Yu ZX, Ferrans V, Epstein SE. Role of reactive oxygen intermediates in cytomegalovirus gene expression and in the response of human smooth muscle cells to viral infection. Circ Res 1996; 79: 1143.
23. Cinatl J, Scholz M, Weber B, et al. Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. Transplant Immunol 1995; 3: 313.
24. Cinatl J Jr, Cinatl J, Rabenau H, Gümbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res 1994; 25: 73.
25. Morel I, Sergent O, Cogrel P, et al. EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radical Biol Med 1995; 2: 303.
26. Pippard MJ, Callender ST. The management of iron chelation therapy. Br J Haematol 1983; 54: 503.
27. Carotenuto P, Pontesilli O, Cambier JC, Hayward AR. Desferoxamine blocks IL-2 receptor expression on human T lymphocytes. J Immunol 1986; 136: 2342.
28. Hoffbrand AV, Ganeshagaru K, Hooton JWL, Tattersall MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976; 33: 517.
29. Zimmermann FA, Davies HS, Knoll PP, Gokel JM, Schmidt T. Orthotopic liver allografts in the rat: the influence of strain combination on the fate of the graft. Transplantation 1984; 37: 406.
30. Kamada N, Calne RY. Orthotopic liver transplantation in the rat: technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979; 28: 47.
31. Bruggeman CA, Meijer H, Dormans PHJ, Debie WHM, Grauls GELM, van Boven CPA. Isolation of a cytomegalovirus-like agent from wild rats. Arch Virol 1982; 73: 231.
32. Bruning JH, Debie WHM, Dormans PHJ, Meijer H, Bruggeman CA. The development and characterization of monoclonal antibodies against rat cytomegalovirus induced antigens. Arch Virol 1987; 94: 55.
33. Lautenschlager I, Höckerstedt K, Taskinen E, et al. Fine needle aspiration cytology of liver allografts in the pig. Transplantation 1984; 38: 330.
34. Lautenschlager I, Höckerstedt K, Ahonen J, et al. Fine-needle aspiration biopsy in the monitoring of liver allografts. II. Applications to human liver allografts. Transplantation 1988; 46: 47.
35. Ascher N, Batts KP, Demetris AJ, et al. International Working Party: terminology for hepatic allograft rejection. Hepatology 1995; 22: 648.
36. Scholz M, Blaheta RA, Hendrich D, et al. Immunomodulatory properties of the metal chelators desferrioxamine and diethylenetriamine penta-acetic acid in vitro. Transplantation 1996; 62: 1371.
37. Blake DR, Hall ND, Bacon PA, Halliwell B, Gutteridge JM. Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 1983; 42: 89.
38. Bradley B, Prowse SJ, Bauling P. Lafferty KJ. Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes 1986; 35; 550.
39. Geist LJ, Hopkins HA, Dai LY, He B, Monick MM, Hunninghake GW. Cytomegalovirus modulates transcription factors necessary for the activation of tumor necrosis factor-α promoter. Am J Respir Cell Mol Biol 1997; 16: 31.
40. Boldogh I, Fons MP, Albrecht T. Increased levels of sequence specific DNA-binding proteins in human cytomegalovirus-infected cells. Biochem Biophys Res Commun 1993; 197: 1505.
41. Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS Jr, Huang ES. Multiple mechanisms are implicated in the regulation of NFκB activity during human cytomegalovirus infection. Proc Natl Acad Sci USA 1993; 90: 1107.
42. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-κB and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retrovir 1995; 11: 1049.
43. Loffreda S, Rai R, Yang SQ, Lin HZ, Diehl AM. Bile ducts and portal and central veins are major producers of tumor necrosis factor α in regenerating rat liver. Gastroenterology 1997; 112: 2089.